Download PDF

1. Company Snapshot

1.a. Company Description

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally.It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics.The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing.


It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services.In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry.Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations.


Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.

Show Full description

1.b. Last Insights on SLV

Selvita S.A. recent performance was negatively driven by the company's Q3 2023 earnings release, which showed a decline in revenue and a net loss. The company's revenue decreased by 14.4% year-over-year, primarily due to lower sales of its proprietary compounds. Additionally, the company's high research and development expenses, which increased by 25.6% year-over-year, likely contributed to the net loss. Furthermore, the company's guidance for 2023 was reduced, indicating a challenging business environment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Drug Discovery Services Company Evaluation Report 2025 | LabCorp, Evotec, and Selvita Lead with Comprehensive Research and Laboratory Services

Aug -14

Source:

Card image cap

European Value Stocks: STIF Société anonyme Among 3 Companies Estimated Below Intrinsic Value

Jul -31

Source:

Card image cap

3 Global Stocks Estimated To Be Up To 42.2% Below Intrinsic Value

Jul -31

Source:

Card image cap

European Stocks That May Be Trading Below Estimated Value In July 2025

Jul -31

Source:

Card image cap

European Stocks Conceivably Undervalued In July 2025

Jul -30

Source:

Card image cap

3 European Stocks Estimated At Up To 41.3% Discount To Intrinsic Value

Jul -30

Source:

Card image cap

European Value Stocks Trading At Estimated Discounts In June 2025

Jun -27

Source:

Card image cap

Discover 3 European Stocks Trading Below Estimated Value

Jun -27

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.26%)

6. Segments

Services Executed in Poland

Expected Growth: 10.27%

Selvita S.A.'s 10.27% growth in Services Executed in Poland is driven by increasing demand for contract research and development services, expansion of existing client relationships, and investments in digital transformation and process optimization. Additionally, Poland's favorable business environment, skilled workforce, and cost competitiveness contribute to the growth.

Services Executed in Croatia

Expected Growth: 10.27%

Selvita S.A.'s services executed in Croatia grew 10.27% driven by increasing demand for R&D outsourcing, expansion of pharmaceutical and biotech companies in the region, and Croatia's favorable business environment. Additionally, Selvita's expertise in integrated drug discovery and development services, as well as its strategic partnerships, contributed to the growth.

Elimination of Intersegment Revenue

Expected Growth: 9.27%

Selvita S.A.'s 9.27% growth is driven by increasing demand for its innovative cancer therapies, strategic partnerships, and expansion into new markets. The company's strong R&D pipeline, cost optimization efforts, and effective sales strategy also contribute to its growth. Additionally, the elimination of intersegment revenue highlights the company's focus on high-margin businesses, further boosting its growth prospects.

7. Detailed Products

Integrated Drug Discovery

Selvita's Integrated Drug Discovery platform offers a comprehensive range of services, from target validation to lead optimization, to help clients accelerate their drug discovery programs.

Contract Research Services

Selvita provides contract research services, including in vitro and in vivo pharmacology, biochemistry, and analytical chemistry, to support clients' research and development programs.

Custom Synthesis

Selvita offers custom synthesis services, providing clients with high-quality, complex organic compounds, including small molecules, peptides, and nucleotides.

Computational Chemistry

Selvita's computational chemistry services utilize advanced modeling and simulation techniques to support clients' drug discovery and development programs.

Medicinal Chemistry

Selvita's medicinal chemistry services focus on the design, synthesis, and optimization of small molecules and peptides to support clients' drug discovery programs.

8. Selvita S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Selvita S.A. operates in a niche market with high barriers to entry, reducing the threat of substitutes.

Bargaining Power Of Customers

Selvita S.A. has a diverse customer base, reducing the bargaining power of individual customers.

Bargaining Power Of Suppliers

Selvita S.A. relies on a few key suppliers, giving them some bargaining power, but the company's size and reputation mitigate this threat.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements and regulatory hurdles, reducing the threat of new entrants.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and a high level of rivalry among them.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 32.82%
Debt Cost 4.23%
Equity Weight 67.18%
Equity Cost 4.23%
WACC 4.23%
Leverage 48.85%

11. Quality Control: Selvita S.A. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Clínica Baviera

A-Score: 6.9/10

Value: 4.1

Growth: 8.2

Quality: 8.4

Yield: 7.5

Momentum: 7.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Voxel

A-Score: 6.7/10

Value: 3.6

Growth: 7.7

Quality: 6.9

Yield: 6.9

Momentum: 9.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Lumibird

A-Score: 3.7/10

Value: 2.3

Growth: 5.4

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Centogene

A-Score: 3.5/10

Value: 10.0

Growth: 1.4

Quality: 5.5

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Vimian Group

A-Score: 2.9/10

Value: 2.1

Growth: 7.2

Quality: 5.5

Yield: 0.0

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Selvita

A-Score: 2.3/10

Value: 3.5

Growth: 4.9

Quality: 3.7

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

46.7$

Current Price

46.7$

Potential

-0.00%

Expected Cash-Flows